



41

Docket No. 60240/JPW/AJM/AJD

1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ilya Trakht et al.  
Serial No.: 09/664,958 Examiner: L. R. Helms  
Filed: September 18, 2000 Group Art Unit: 1642  
For: NOVEL TUMOR-ASSOCIATED MARKER

RECEIVED  
NOV 25 2003  
TECH CENTER 1600/2900

1185 Avenue of the Americas  
New York, New York 10036  
November 12, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(c)(1) and §1.97(e)(1) to supplement the Information Disclosure Statements filed July 30, 2003 and September 19, 2003 in connection with the above-identified application.

According to 37 C.F.R. §1.97(c), an Information Disclosure Statement shall be considered by the U.S. Patent and Trademark Office if filed before the mailing date of any of a Final Office Action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or any other Office Action which closes prosecution in the application, provided that the Information Disclosure Statement is accompanied by either (1) the statement specified in 37 C.F.R. §1.97(e)(1) or §1.97(e)(2), or (2) the fee set forth in 37 C.F.R. §1.17(p). Applicants annex hereto as **Exhibit A** a statement under 37 C.F.R. §1.97(e)(1), stating that each item of information contained in this Supplemental Information Disclosure Statement was first cited in an International Search Report issued in connection with a foreign counterpart of the subject application, not more than three months prior to the filing of this Supplemental Information Disclosure Statement. A copy of this Search Report is attached

Applicants: Ilya Trakht et al.  
Serial No.: 09/664,958  
Filed: September 18, 2000  
Page 2

hereto as **Exhibit B**.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit C**), and attached hereto as **Exhibits 1-5**:

1. PCT International Application No. PCT/GB90/02017, filed December 21, 1990, International Publication No. WO 91/09967, published July 11, 1991 (**Exhibit 1**);
2. Campbell AM (1986) Monoclonal Antibody Technology. Elsevier Publishing Co., New York, pp. 1-32 (**Exhibit 2**);
3. De Vries L, Lou X, Zhao G, Zheng B and Farquhar MG (1998) GIPC, a PDZ domain containing protein, interacts specifically with the C terminus of RGS-GAIP. Proc. Natl. Acad. Sci. USA 95: 12340-12345 (**Exhibit 3**);
4. Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM et al. (1994) Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7: 13-21 (**Exhibit 4**); and
5. Rousset R, Fabre S, Desbois C, Bantignies F and Jalinot P (1998) The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins. Oncogene 16: 643-654 (**Exhibit 5**).

Applicants note that the fourth reference (Harlow and Lane, 1988) cited in the October 17, 2003 International Search Report (**Exhibit B**) has not been listed in the present Supplemental Information Disclosure Statement because this reference was previously made of record in the subject application, having been


Applicants: Ilya Trakht et al.  
Serial No.: 09/664,958  
Filed: September 18, 2000  
Page 3

cited to the Examiner in the Supplemental Information Disclosure Statement filed July 30, 2003.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,




John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the  
Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Commissioner for Patents  
P.O. Box 1450, Alexandria  
VA 22313-1450

Alan J. Morrison  
Reg. No. 37,399

11/12/03  
Date



|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|--|----|--|---|---------------------------------|---|---|---|-------------|------------------------|--------------|-----------------|---------------------------------------|-----------|
| <b>Form PTO-1479</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary)  |    | <b>Atty. Docket No.</b><br>60240/JPW/AJM/AJD   |   | <b>Serial No.</b><br>09/664,958 |   |   |   |             |                        |              |                 |                                       |           |
|  |    | <b>Applicant(s)</b><br>Ilya Trakht et al.  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    | <b>Filing Date</b><br>September 18, 2000   |   | <b>Art Unit</b><br>1642         |   |   |   |             |                        |              |                 |                                       |           |
| <b>U.S. PATENT DOCUMENTS</b>   |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
| <b>Examiner<br/>Initials</b>   |    | <b>Document Number</b>   |   |                                 |   |   |   | <b>Date</b> | <b>Name</b>            | <b>Class</b> | <b>Subclass</b> | <b>Filing Date<br/>If Appropriate</b> |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
| <b>FOREIGN PATENT DOCUMENTS</b>  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    | <b>Document Number</b>   |   |                                 |   |   |   | <b>Date</b> | <b>Country</b>         | <b>Class</b> | <b>Subclass</b> | <b>Translation</b>                    |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 | <b>Yes</b>                            | <b>No</b> |
|  | WO | 9  | 1 | 0                               | 9 | 9 | 6 | 7           | 07/11/91               | PCT          |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
| <b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    | Campbell AM (1986) Monoclonal Antibody Technology. Elsevier Publishing Co., New York, pp. 1-32;  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    | De Vries L, Lou X, Zhao G, Zheng B and Farquhar MG (1998) GIPC, a PDZ domain containing protein, interacts specifically with the C terminus of RGS-GAIP. Proc. Natl. Acad. Sci. USA 95: 12340-12345;         |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    | Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM et al. (1994) Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7: 13-21; and |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    | Rousset R, Fabre S, Desbois C, Bantignies F and Jalinot P (1998) The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins. Oncogene 16: 643-654.           |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
|  |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |
| <b>EXAMINER</b>  |    |  |   |                                 |   |   |   |             | <b>DATE CONSIDERED</b> |              |                 |                                       |           |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |    |  |   |                                 |   |   |   |             |                        |              |                 |                                       |           |



Docket No. 60240/JPW/AJM/AJD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ilya Trakht et al.  
Serial No.: 09/664,958 Examiner: L. R. Helms  
Filed: September 18, 2000 Group Art Unit: 1642  
For: NOVEL TUMOR-ASSOCIATED MARKER

1185 Avenue of the Americas  
New York, New York 10036  
November 12, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RECEIVED**

**NOV 25 2003**

**TECH CENTER 1600/2900**

Statement Under 37 C.F.R. §1.97(e)(1)

Pursuant to 37 C.F.R. §1.97(e)(1), applicants hereby state that each item of information contained in this Supplemental Information Disclosure Statement was first cited in an International Search Report issued October 17, 2003 in connection with International PCT Application No. PCT/US01/29242, a foreign counterpart of the subject application, not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Respectfully submitted,

John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400